Therapeutic Area Expertise

Committed to advancing innovative therapies that make a meaningful difference in patients' lives.

From industry-firsts to well-researched indications, MMS brings a wealth of specialized knowledge across therapeutic areas to ensure that your drug development programs are supported by a team that truly understands the unique challenges and opportunities presented. We are proficient in a diverse range of therapeutic areas, including rare diseases, psychedelics, oncology and radiopharmaceuticals, central nervous system (CNS) disorders, and many others. Our deep understanding of these complex indications, combined with our data-driven approach and cutting-edge technology, allows us to be your trusted partner.

Whether you are pioneering new treatments for rare diseases, exploring the potential of psychedelics, or developing groundbreaking oncology therapies, MMS can bring your program to life through comprehensive solutions that focus on the long-term health of your project.

Review our therapeutic area expertise to understand how MMS can help you achieve your development goals across a variety of indications.

In addition to the pivotal therapeutic areas above, MMS global colleagues possess a depth and breadth of industry expertise that is unmatched in other areas.

Suggested For You

perspectives

April 20th, 2026

The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain

perspectives

April 15th, 2026

Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks

perspectives

April 8th, 2026

Four Pillars of My Success as a Clinical Trial Transparency Specialist

webinar

March 26th, 2026

Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials

perspectives

March 25th, 2026

REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons

perspectives

March 12th, 2026

AI in Pharma: Autopilot Is Not the Same as Removing the Pilot 

webinar

April 30th, 2026

Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors

perspectives

March 3rd, 2026

Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design

perspectives

February 25th, 2026

Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development